{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T14:33:02Z","timestamp":1779287582997,"version":"3.51.4"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.intimp.2016.02.001","type":"journal-article","created":{"date-parts":[[2016,2,11]],"date-time":"2016-02-11T13:37:52Z","timestamp":1455197872000},"page":"70-82","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Oral administration of acarbose ameliorates imiquimod-induced psoriasis-like dermatitis in a mouse model"],"prefix":"10.1016","volume":"33","author":[{"given":"Hsin-Hua","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-Hsuan","family":"Chao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Der-Yuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deng-Ho","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting-Wen","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Rong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi Chen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2016.02.001_bb0005","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMra0804595","article-title":"Psoriasis","volume":"361","author":"Nestle","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2016.02.001_bb0010","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1001\/2013.jamadermatol.406","article-title":"Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis","volume":"149","author":"Armstrong","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.intimp.2016.02.001_bb0015","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00403-011-1200-6","article-title":"Psoriasis increased the risk of diabetes: a meta-analysis","volume":"304","author":"Cheng","year":"2012","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.intimp.2016.02.001_bb0020","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/HJH.0b013e32835bcce1","article-title":"The association between psoriasis and hypertension: a systematic review and meta-analysis of observational studies","volume":"31","author":"Armstrong","year":"2013","journal-title":"J Hyperten"},{"key":"10.1016\/j.intimp.2016.02.001_bb0025","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/bjd.12101","article-title":"The association between psoriasis and dyslipidaemia: a systematic review","volume":"168","author":"Ma","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.intimp.2016.02.001_bb0030","doi-asserted-by":"crossref","DOI":"10.1038\/nutd.2012.26","article-title":"The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies","volume":"2","author":"Armstrong","year":"2012","journal-title":"Nutr Diabetes"},{"key":"10.1016\/j.intimp.2016.02.001_bb0035","doi-asserted-by":"crossref","first-page":"4992","DOI":"10.1016\/j.ijcard.2013.07.127","article-title":"Psoriasis and risk of cardiovascular disease: a meta-analysis of cohort studies","volume":"168","author":"Gu","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.intimp.2016.02.001_bb0040","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/nature05663","article-title":"Pathogenesis and therapy of psoriasis","volume":"445","author":"Lowes","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2016.02.001_bb0045","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s12016-012-8307-1","article-title":"Role of IL-17 in psoriasis and psoriatic arthritis","volume":"44","author":"Raychaudhuri","year":"2013","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.intimp.2016.02.001_bb0050","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.autrev.2014.01.008","article-title":"Diagnosis and classification of psoriasis","volume":"13","author":"Raychaudhuri","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.intimp.2016.02.001_bb0055","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/jid.2012.194","article-title":"The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings","volume":"133","author":"Martin","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.intimp.2016.02.001_bb0060","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jaad.2007.09.010","article-title":"Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial","volume":"58","author":"Menter","year":"2008","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.intimp.2016.02.001_bb0065","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2016.02.001_bb0070","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1038\/jid.2012.163","article-title":"Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: results from a phase I, randomized, placebo-controlled trial","volume":"132","author":"Papp","year":"2012","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.intimp.2016.02.001_bb0075","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jaci.2015.01.018","article-title":"Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial","volume":"136","author":"Krueger","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.intimp.2016.02.001_bb0080","doi-asserted-by":"crossref","first-page":"357","DOI":"10.2147\/DMSO.S28340","article-title":"Critical evaluation of the role of acarbose in the treatment of diabetes: patient considerations","volume":"5","author":"Rosak","year":"2012","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.intimp.2016.02.001_bb0085","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ejphar.2010.11.015","article-title":"Acarbose actions on insulin resistance and inflammatory parameters during an oral fat load","volume":"651","author":"Derosa","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.intimp.2016.02.001_bb0090","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/1753-0407.12232","article-title":"Acarbose treatment affects the serum levels of inflammatory cytokines and the gut content of bifidobacteria in Chinese patients with type 2 diabetes mellitus","volume":"7","author":"Su","year":"2015","journal-title":"J Diabetes"},{"key":"10.1016\/j.intimp.2016.02.001_bb0095","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s11883-014-0435-z","article-title":"Inflammation and cardiovascular disease: from pathogenesis to therapeutic target","volume":"16","author":"Golia","year":"2014","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.intimp.2016.02.001_bb0100","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1001\/archderm.140.12.1490","article-title":"Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors","volume":"140","author":"Gilliet","year":"2004","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.intimp.2016.02.001_bb0105","doi-asserted-by":"crossref","first-page":"5836","DOI":"10.4049\/jimmunol.0802999","article-title":"Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23\/IL-17 axis","volume":"182","author":"van der Fits","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2016.02.001_bb0110","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1002\/eji.201343801","article-title":"TLRs to cytokines: mechanistic insights from the imiquimod mouse model of psoriasis","volume":"43","author":"Flutter","year":"2013","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.intimp.2016.02.001_bb0115","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/jid.2012.318","article-title":"An alternative pathway of imiquimod-induced psoriasis- like skin inflammation in the absence of interleukin-17 receptor a signaling","volume":"133","author":"El Malki","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.intimp.2016.02.001_bb0120","doi-asserted-by":"crossref","first-page":"462","DOI":"10.4049\/jimmunol.1102224","article-title":"IL-22 is required for imiquimod-induced psoriasiform skin inflammation in mice","volume":"188","author":"Van Belle","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.intimp.2016.02.001_bb0125","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/nature07240","article-title":"ATP drives lamina propria T(H)17 cell differentiation","volume":"455","author":"Atarashi","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2016.02.001_bb0130","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.coi.2008.03.006","article-title":"gammadelta T cells: an important source of IL-17","volume":"20","author":"Roark","year":"2008","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.intimp.2016.02.001_bb0135","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/1479164112441524","article-title":"Alpha-glucosidase inhibitors 2012 \u2014 cardiovascular considerations and trial evaluation","volume":"9","author":"Standl","year":"2012","journal-title":"Diab Vasc Dis Res"},{"key":"10.1016\/j.intimp.2016.02.001_bb0140","article-title":"In vivo induction of Tr1 cells via mucosal dendritic cells and AHR signaling","volume":"6","author":"Wu","year":"2011","journal-title":"PloSOne"},{"key":"10.1016\/j.intimp.2016.02.001_bb0145","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1177\/039463200601900204","article-title":"Leukocyte infiltration and mRNA expression of IL-20, IL-8 and TNF-R P60 in psoriatic skin is driven by TNF-alpha","volume":"19","author":"Ogilvie","year":"2006","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"10.1016\/j.intimp.2016.02.001_bb0150","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3899\/jrheum.120256","article-title":"Interleukin 6 blockade: tocilizumab in psoriatic arthritis","volume":"89","author":"Atzeni","year":"2012","journal-title":"J Rheumatol Suppl"},{"key":"10.1016\/j.intimp.2016.02.001_bb0155","doi-asserted-by":"crossref","first-page":"161","DOI":"10.4103\/0019-5154.62754","article-title":"Biological therapy of psoriasis","volume":"55","author":"Sivamani","year":"2010","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.intimp.2016.02.001_bb0160","article-title":"Acarbose reduces blood glucose by activating miR-10a-5p and miR-664 in diabetic rats","volume":"8","author":"Zhang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2016.02.001_bb0165","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.4049\/jimmunol.1001001","article-title":"IL-23-mediated psoriasis-like epidermal hyperplasia is dependent on IL-17A","volume":"186","author":"Rizzo","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2016.02.001_bb0170","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nature04753","article-title":"Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells","volume":"441","author":"Bettelli","year":"2006","journal-title":"Nature"},{"issue":"31","key":"10.1016\/j.intimp.2016.02.001_bb0175","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.immuni.2009.06.020","article-title":"Interleukin-17-producing gammadelta T cells selectively expand in response to pathogen products and environmental signals","volume":"21","author":"Martin","year":"2009","journal-title":"Immunity"},{"issue":"35","key":"10.1016\/j.intimp.2016.02.001_bb0180","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.immuni.2011.08.001","article-title":"Pivotal role of dermal IL-17-producing gammadelta T cells in skin inflammation","volume":"28","author":"Cai","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2016.02.001_bb0185","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1002\/eji.200838331","article-title":"Interleukin 10 suppresses Th17 cytokines secreted by macrophages and T cells","volume":"38","author":"Gu","year":"2008","journal-title":"Eur. J. Immunol."},{"issue":"31","key":"10.1016\/j.intimp.2016.02.001_bb0190","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.immuni.2009.08.011","article-title":"Regulatory T cells reinforce intestinal homeostasis","volume":"18","author":"Barnes","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2016.02.001_bb0195","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1097\/00054725-200409000-00027","article-title":"Regulatory T cells: peace keepers in the gut","volume":"10","author":"Allez","year":"2004","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.intimp.2016.02.001_bb0200","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3389\/fimmu.2014.00318","article-title":"Blowing on embers: commensal microbiota and our immune system","volume":"5","author":"Spasova","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2016.02.001_bb0205","first-page":"47","article-title":"Effect of acarbose on fecal bifidobacteria content in patients with type 2 diabetes mellitus","volume":"27","author":"Liu","year":"2011","journal-title":"Chin J Endocrinol Metab"},{"key":"10.1016\/j.intimp.2016.02.001_bb0210","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002714","article-title":"Probiotic Bifidobacterium breve induces IL-10-producing Tr1 cells in the colon","volume":"8","author":"Jeon","year":"2012","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.intimp.2016.02.001_bb0215","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.jff.2013.07.005","article-title":"Hesperidin inhibits development of atopic dermatitis-like skin lesions in NC\/Nga mice by suppressing Th17 activity","volume":"5","author":"Nagashioa","year":"2013","journal-title":"J. Funct. Foods"},{"key":"10.1016\/j.intimp.2016.02.001_bb0220","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1038\/sj.emboj.7600183","article-title":"Latent TGFbeta1 overexpression in keratinocytes results in a severe psoriasis-like skin disorder","volume":"23","author":"Li","year":"2004","journal-title":"EMBO J"},{"key":"10.1016\/j.intimp.2016.02.001_bb0225","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1046\/j.1365-2133.2001.04178.x","article-title":"Severe combined immunodeficiency mouse\u2013human skin chimeras: a unique animal model for the study of psoriasis and cutaneous inflammation","volume":"144","author":"Raychaudhuri","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.intimp.2016.02.001_bb0230","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1038\/jid.2008.38","article-title":"FR255734, a humanized, Fc-Silent, Anti-CD28 antibody, improves psoriasis in the SCID mouse-psoriasis xenograft model","volume":"128","author":"Raychaudhuri","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.intimp.2016.02.001_bb0235","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1038\/jid.2013.3","article-title":"1alpha,25-Dihydroxyvitamin-D3-3-bromoacetate regulates AKT\/mTOR signaling cascades: a therapeutic agent for psoriasis","volume":"133","author":"Datta Mitra","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.intimp.2016.02.001_bb0240","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2174\/187153012802002901","article-title":"Classical to current approach for treatment of psoriasis: a review","volume":"12","author":"Rahman","year":"2012","journal-title":"Endocr Metab Immune Disord Drug Targets"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576916300364?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576916300364?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,7,16]],"date-time":"2018-07-16T14:53:17Z","timestamp":1531752797000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576916300364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":48,"alternative-id":["S1567576916300364"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2016.02.001","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral administration of acarbose ameliorates imiquimod-induced psoriasis-like dermatitis in a mouse model","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2016.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}